Hyaluronidase-Facilitated High-Dose Subcutaneous IgG Effectively Controls Parvovirus B19 Infection in a Pediatric Cardiac Transplant Patient With Severe T-Cell Lymphopenia
parvovirus B19, heart transplant, pediatric, immunodeficiency, subcutaneous immunoglobulin
We treated three pediatric cardiac transplant patients with chronic parvovirus viremia with high-dose intravenous immunoglobulin (HD-IVIG). One patient with severe T-cell lymphopenia suffered recurrent viremia and aseptic meningitis, which resolved remarkably when he was switched to high-dose hyaluronidase-facilitated subcutaneous immunoglobulin (HD-SCIG-Hy). We discuss the advantages of HD-SCIG-Hy vs HD-IVIG treatment for similar cases.
Digital Object Identifier (DOI)
Citation / Publisher Attribution
Open Forum Infectious Diseases, v. 7, issue 5, art. ofaa076
Scholar Commons Citation
Cruz, Rachel J.; Dasso, Joseph F.; Duff, Carla; Krasnopero, Diane; Long, Zsofia; Ellison, Maryssa; Nieves, Daime; Sriaroon, Panida; Asante-Korang, Alfred; and Walter, Jolan, "Hyaluronidase-Facilitated High-Dose Subcutaneous IgG Effectively Controls Parvovirus B19 Infection in a Pediatric Cardiac Transplant Patient With Severe T-Cell Lymphopenia" (2020). Pediatrics Faculty Publications. 1.
Was this content written or created while at USF?